Core Insights - Novo shares experienced a significant decline following the failure of its experimental obesity drug to outperform Lilly's treatment in an 84-week clinical trial [1] Company Summary - The Danish drugmaker Novo's experimental obesity drug did not achieve better results compared to Lilly's treatment, leading to a drop in its stock price [1] Industry Summary - The competitive landscape in the obesity treatment market is intensifying, with Lilly's treatment currently showing superior efficacy in clinical trials compared to Novo's offering [1]